Genentech Plans Herceptin Early-Stage Breast Cancer Submission
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech is planning a supplemental BLA for Herceptin (trastuzumab) for adjuvant treatment of early stage breast cancer. Much-lauded Phase III data at American Society of Clinical Oncology meeting show significant reduction in disease recurrence and overall survival improvement of 49% at four years.
You may also be interested in...
One Year On Roche’s Herceptin Is Best, Studies Show
Two closely watched studies on Herceptin (trastuzumab) suggest neither a shorter nor a longer period of treatment is better at fighting off a recurrence of cancer than the current standard of one year. Roche’s final analysis of HERA and France’s six-month attempt in PHARE were presented Oct. 1 at ESMO.
National Cancer Institute Kicks Off Head-To-Head Tykerb vs. Herceptin Study
Enrollment could exceed global targets, principal investigator tells “The Pink Sheet” Daily.
National Cancer Institute Kicks Off Head-To-Head Tykerb vs. Herceptin Study
Enrollment could exceed global targets, principal investigator tells “The Pink Sheet” Daily.